{"name":"Eric Stephen Winer, MD","slug":"eric-stephen-winer-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BXCL701","genericName":"BXCL701","slug":"bxcl701","indication":"Systemic lupus erythematosus (SLE)","status":"phase_2"}]}],"pipeline":[{"name":"BXCL701","genericName":"BXCL701","slug":"bxcl701","phase":"phase_2","mechanism":"BXCL701 is a selective inhibitor of sphingosine-1-phosphate receptor 1 (S1P1) that modulates immune cell trafficking and reduces pathological inflammation.","indications":["Systemic lupus erythematosus (SLE)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE91ZlhTdjJZQkp6MVExWVl0QkNsclJLYkY0Yy1QRjYzV3l0aFp3WEZmYTRMT1hYR3ptWFI4R3dSVDh0enNCQVVQbmFpUThSamsxclBmbWUzV01IWG1ka2tYUHF3Q0pHUHljaUE?oc=5","date":"2025-07-13","type":"regulatory","source":"Wiley Online Library","summary":"Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML - Sallman - 2025 - HemaSphere - Wiley Online Library","headline":"Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML - ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQNlNYNmJrTzBwSEQ4VmRsbXJocFZnMzFOTGgxd1VadTdmZ09NQXo2dlJTTFRxWUxWam9lWnd6TUlXdWM1WkZiOGlZc2tsdE1naUphWV9LcjFWZnlMYlhzN1I5cHJveTY0b0hLeVkwVktFQ1JMMDNtM1N0M1N4NjMxSFRwRU5WSFlYM2xVdmlNQzRFMkhaWDZ3cGI2YTdTNFBWRF9oZUFvb3k2TWc?oc=5","date":"2025-04-14","type":"pipeline","source":"Yale School of Medicine","summary":"Lung Cancer Treatment Advancements with Yale expert Dr. Roy S. Herbst - Yale School of Medicine","headline":"Lung Cancer Treatment Advancements with Yale expert Dr. Roy S. Herbst","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNVDBlOU54Wm1TUHNOcEgwMGhoVzQtcnpDMk1mQi1sanNxNGJVX0FxUmQyakdBaGJEcE4xNzRQWWJIRDZWSnp6TDItMGVQS1dQaFRtVTdaMTdtUVRKaGF0ZWNTUVpVeXB0Q0pKU2I2dlY4RlJwNUNWYmRxOGNiTWRUTk0wVlFvMEtRTlI5VHdkQUpwVlZoZDRkZ0NCVXJBVUc0MjNiWXd3Y2ZERjgzcW1DdWVwVTVZMUp1VllwUQ?oc=5","date":"2024-06-19","type":"regulatory","source":"OncLive","summary":"Emavusertib Monotherapy Shows Antitumor Activity, Safety in Select R/R AML and High-Risk MDS - OncLive","headline":"Emavusertib Monotherapy Shows Antitumor Activity, Safety in Select R/R AML and High-Risk MDS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBRcGZtZ1F4WEhSSmktRXJSdUU2ejU4cDNBeDNNS3NoYjQxTm1jX0oxZzgyajA5VDU3YXBEXzdQeV8xSU9HWGRXa2xSNGtmOXJWOERzQTk5dkZadk1fXzNmbHhMS0JrRkU?oc=5","date":"2023-09-21","type":"pipeline","source":"NEJM Evidence","summary":"Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia - NEJM Evidence","headline":"Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPUS02Z1ZqczZ6VmZpNjZWLWpEN1VwRHl6WVhodFhjRWZpRXBqa05EcjYzbXpJaVVSb1h4cnZac0djYnpNVU5QYzJFaWp1MlVmZXpDSTVQa3AyMkd4YjdISjIwYzNDSXk5ZjZPTjdNSTBDWF9jWWxZeE5OTFBxMzZFQUFlalFmaXRlNEpJZHdiVU14NHRpc2daUUJWX1h6OWVfNS1JaGFPdl9makJBV1E?oc=5","date":"2023-05-31","type":"pipeline","source":"Yale School of Medicine","summary":"Yale Cancer Center Grand Rounds/Paul Calabresi, MD Memorial Lectureship - Yale School of Medicine","headline":"Yale Cancer Center Grand Rounds/Paul Calabresi, MD Memorial Lectureship","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}